Gedeon Richter Joins Association Pro Biosimilars

The Association Pro biosimilars has grown. On March 1, 2016,  Gedeon Richter Pharma GmbH became part of the Association Pro biosimilars.

"Gedeon Richter is an active member of the European biosimilars Group and thus is already involved at the European level per biosimilars. We are delighted that we now work together within the framework of the Association Pro biosimilars in order to make the framework for biosimilars in Germany sustainable" Dr. Andreas Eberhorn, Chairman of the Association Pro biosimilars.

"Biosimilars can make an important contribution to enable the on-demand access of patients to modern biopharmaceutical drugs and affordable supply. However, this will need fair and sustainable competition. To achieve these goals, we want to join together with the other participants of JSC" said Tibor Horváth, CEO of Gedeon Richter Pharma GmbH.

Gedeon Richter Plc. Headquartered in Budapest, Hungary, is one of the largest pharmaceutical companies in Central Eastern Europe. With its gynocology business, Gedeon Richter is also represented on the Western European market. In 2015, Gedeon Richter generated consolidated revenues of about 1.2 billion EUR (1.4 billion USD) and reached a market capitalization of 2.3 billion EUR (2.7 billion USD). The product portfolio includes many important therapeutic areas, including gynecology, diseases of the central nervous system (CNS) and the cardiovascular system. The company has the largest research and development department in Central and Eastern Europe; The research program focuses on diseases of the CNS. Due to its generally acknowledged steroid chemistry expertise, Gedeon Richter plays a significant role in the field of women's health worldwide. Advancing the development of biosimilar products is also a strategic focus of Gedeon Richter.

The AG Pro biosimilars represents the interests of Biosimilarunternehmen in Germany. It is open to all companies that develop biosimilars, and that manufacture and provide for the supply of these cost-effective biologics. The working group under the auspices of the Pro Generika eV is committed to exposing patients to and increasing their access to modern biopharmaceutical drug therapies for affordable care and for fair and sustainable competition.